AB0740 The frequency of occult hepatitis b infection in rheumatic diseases and the role of anti-hbc test in routine practice
Identifieur interne : 003C33 ( Main/Exploration ); précédent : 003C32; suivant : 003C34AB0740 The frequency of occult hepatitis b infection in rheumatic diseases and the role of anti-hbc test in routine practice
Auteurs : S. Yilmaz ; K. Sener [Turquie] ; I. Simsek ; M. Cinar ; R. Gumral [Turquie] ; H. Erdem ; A. Kubar [Turquie] ; S. PaySource :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
Abstract
Background Most of the drugs used in rheumatic diseases suppress the immune system, especially corticosteroids and anti-TNF agents, therefore may cause reactivation in patients with hepatitis B virus (HBV). Studies have shown that HBV reactivation due to immunosuppression is not a case only in patients with chronic HBV infection, but also in patients with occult diseases. The presence of HBV DNA in liver tissue and/or in serum in the absence of detectable hepatitis B surface antigen (HBsAg) is called occult HBV infection. Evidence is accumulating that HBV is present in patients who are HBsAg negative, but have antibody to hepatitis B core antigen (anti-HBc) Therefore, guidelines recommend that anti-HBc IgG tests should be added to HBsAg and anti-HBs tests before initiation of immunosuppressive therapy. Objectives In the present study we aimed to determine the prevalence of occult HBV infection in patients receiving immunosuppressive agents and examine the role of anti-HBc as a screening test for occult infection in Turkish patients with rheumatic diseases. Methods Consecutive patients using immunosuppressive agents for rheumatic diseases seen in rheumatology outpatient clinic and who are negative for HBsAg were included. The demographic features, received treatment in last 3 months and liver function tests of all patients were recorded. HBsAg, Anti-HBs and anti-HBc IgG tests were studied in all participants along with the quantification of HBV-DNA by real-time PCR. Results Total 116 patients included to the study (59 spondylarthritis, 39 romatoid arthritis, and 18 others). The demographic features and received treatment in last 3 months were presented in Table 1. In this HBsAg negative group, 27 patients (23%) were found to be positive for anti-HBc IgG. In this subgroup, 19 patients were anti-HBs Ab positive while isolated anti-HBc IgG positivity were detected in other 8 patients. None of the patients was found as HBV-DNA positive. Conclusions Since none of our patients with isolated anti-HBc positivity had detectable levels of HBV-DNA in their serum, using anti-HBc test for screening seems not to be justified. While our results suggest that prevalence of occult HBV infection is ignorable among patients with rheumatic diseases in Turkey, considering the preliminary feature of our results (target study population is 300) full results should be waited to reach such a definite conclusion. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.3062
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 004669
- to stream Istex, to step Curation: 004669
- to stream Istex, to step Checkpoint: 000261
- to stream Main, to step Merge: 003C42
- to stream Main, to step Curation: 003C33
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">AB0740 The frequency of occult hepatitis b infection in rheumatic diseases and the role of anti-hbc test in routine practice</title>
<author><name sortKey="Yilmaz, S" sort="Yilmaz, S" uniqKey="Yilmaz S" first="S." last="Yilmaz">S. Yilmaz</name>
</author>
<author><name sortKey="Sener, K" sort="Sener, K" uniqKey="Sener K" first="K." last="Sener">K. Sener</name>
</author>
<author><name sortKey="Simsek, I" sort="Simsek, I" uniqKey="Simsek I" first="I." last="Simsek">I. Simsek</name>
</author>
<author><name sortKey="Cinar, M" sort="Cinar, M" uniqKey="Cinar M" first="M." last="Cinar">M. Cinar</name>
</author>
<author><name sortKey="Gumral, R" sort="Gumral, R" uniqKey="Gumral R" first="R." last="Gumral">R. Gumral</name>
</author>
<author><name sortKey="Erdem, H" sort="Erdem, H" uniqKey="Erdem H" first="H." last="Erdem">H. Erdem</name>
</author>
<author><name sortKey="Kubar, A" sort="Kubar, A" uniqKey="Kubar A" first="A." last="Kubar">A. Kubar</name>
</author>
<author><name sortKey="Pay, S" sort="Pay, S" uniqKey="Pay S" first="S." last="Pay">S. Pay</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:95916040E8B6DCBB2255B2D91D3530CD33E052CE</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2013-eular.3062</idno>
<idno type="url">https://api.istex.fr/document/95916040E8B6DCBB2255B2D91D3530CD33E052CE/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004669</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004669</idno>
<idno type="wicri:Area/Istex/Curation">004669</idno>
<idno type="wicri:Area/Istex/Checkpoint">000261</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000261</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Yilmaz S:ab:the:frequency</idno>
<idno type="wicri:Area/Main/Merge">003C42</idno>
<idno type="wicri:Area/Main/Curation">003C33</idno>
<idno type="wicri:Area/Main/Exploration">003C33</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">AB0740 The frequency of occult hepatitis b infection in rheumatic diseases and the role of anti-hbc test in routine practice</title>
<author><name sortKey="Yilmaz, S" sort="Yilmaz, S" uniqKey="Yilmaz S" first="S." last="Yilmaz">S. Yilmaz</name>
<affiliation><wicri:noCountry code="no comma">Division Of Rheumatology</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Sener, K" sort="Sener, K" uniqKey="Sener K" first="K." last="Sener">K. Sener</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Microbiology, Gulhane School Of Medicine, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Simsek, I" sort="Simsek, I" uniqKey="Simsek I" first="I." last="Simsek">I. Simsek</name>
<affiliation><wicri:noCountry code="no comma">Division Of Rheumatology</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Cinar, M" sort="Cinar, M" uniqKey="Cinar M" first="M." last="Cinar">M. Cinar</name>
<affiliation><wicri:noCountry code="no comma">Division Of Rheumatology</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gumral, R" sort="Gumral, R" uniqKey="Gumral R" first="R." last="Gumral">R. Gumral</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Microbiology, Gulhane School Of Medicine, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Erdem, H" sort="Erdem, H" uniqKey="Erdem H" first="H." last="Erdem">H. Erdem</name>
<affiliation><wicri:noCountry code="no comma">Division Of Rheumatology</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kubar, A" sort="Kubar, A" uniqKey="Kubar A" first="A." last="Kubar">A. Kubar</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Microbiology, Gulhane School Of Medicine, Ankara</wicri:regionArea>
<wicri:noRegion>Ankara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pay, S" sort="Pay, S" uniqKey="Pay S" first="S." last="Pay">S. Pay</name>
<affiliation><wicri:noCountry code="no comma">Division Of Rheumatology</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">72</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="A1014">A1014</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
<idno type="istex">95916040E8B6DCBB2255B2D91D3530CD33E052CE</idno>
<idno type="DOI">10.1136/annrheumdis-2013-eular.3062</idno>
<idno type="href">annrheumdis-72-A1014-3.pdf</idno>
<idno type="ArticleID">annrheumdis-2013-eular.3062</idno>
<idno type="local">annrheumdis;72/Suppl_3/A1014-c</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background Most of the drugs used in rheumatic diseases suppress the immune system, especially corticosteroids and anti-TNF agents, therefore may cause reactivation in patients with hepatitis B virus (HBV). Studies have shown that HBV reactivation due to immunosuppression is not a case only in patients with chronic HBV infection, but also in patients with occult diseases. The presence of HBV DNA in liver tissue and/or in serum in the absence of detectable hepatitis B surface antigen (HBsAg) is called occult HBV infection. Evidence is accumulating that HBV is present in patients who are HBsAg negative, but have antibody to hepatitis B core antigen (anti-HBc) Therefore, guidelines recommend that anti-HBc IgG tests should be added to HBsAg and anti-HBs tests before initiation of immunosuppressive therapy. Objectives In the present study we aimed to determine the prevalence of occult HBV infection in patients receiving immunosuppressive agents and examine the role of anti-HBc as a screening test for occult infection in Turkish patients with rheumatic diseases. Methods Consecutive patients using immunosuppressive agents for rheumatic diseases seen in rheumatology outpatient clinic and who are negative for HBsAg were included. The demographic features, received treatment in last 3 months and liver function tests of all patients were recorded. HBsAg, Anti-HBs and anti-HBc IgG tests were studied in all participants along with the quantification of HBV-DNA by real-time PCR. Results Total 116 patients included to the study (59 spondylarthritis, 39 romatoid arthritis, and 18 others). The demographic features and received treatment in last 3 months were presented in Table 1. In this HBsAg negative group, 27 patients (23%) were found to be positive for anti-HBc IgG. In this subgroup, 19 patients were anti-HBs Ab positive while isolated anti-HBc IgG positivity were detected in other 8 patients. None of the patients was found as HBV-DNA positive. Conclusions Since none of our patients with isolated anti-HBc positivity had detectable levels of HBV-DNA in their serum, using anti-HBc test for screening seems not to be justified. While our results suggest that prevalence of occult HBV infection is ignorable among patients with rheumatic diseases in Turkey, considering the preliminary feature of our results (target study population is 300) full results should be waited to reach such a definite conclusion. Disclosure of Interest None Declared</div>
</front>
</TEI>
<affiliations><list><country><li>Turquie</li>
</country>
</list>
<tree><noCountry><name sortKey="Cinar, M" sort="Cinar, M" uniqKey="Cinar M" first="M." last="Cinar">M. Cinar</name>
<name sortKey="Erdem, H" sort="Erdem, H" uniqKey="Erdem H" first="H." last="Erdem">H. Erdem</name>
<name sortKey="Pay, S" sort="Pay, S" uniqKey="Pay S" first="S." last="Pay">S. Pay</name>
<name sortKey="Simsek, I" sort="Simsek, I" uniqKey="Simsek I" first="I." last="Simsek">I. Simsek</name>
<name sortKey="Yilmaz, S" sort="Yilmaz, S" uniqKey="Yilmaz S" first="S." last="Yilmaz">S. Yilmaz</name>
</noCountry>
<country name="Turquie"><noRegion><name sortKey="Sener, K" sort="Sener, K" uniqKey="Sener K" first="K." last="Sener">K. Sener</name>
</noRegion>
<name sortKey="Gumral, R" sort="Gumral, R" uniqKey="Gumral R" first="R." last="Gumral">R. Gumral</name>
<name sortKey="Kubar, A" sort="Kubar, A" uniqKey="Kubar A" first="A." last="Kubar">A. Kubar</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:95916040E8B6DCBB2255B2D91D3530CD33E052CE |texte= AB0740 The frequency of occult hepatitis b infection in rheumatic diseases and the role of anti-hbc test in routine practice }}
This area was generated with Dilib version V0.6.31. |